DB07107
DB07107 is a potent agent resistant T315I mutant Bcr-Abl tyrosine kinase inhibitor. DB07107 is also a potent Akt1 inhibitor with an IC50 value of 360 nM.
For research use only. We do not sell to patients.
- CAS No.: 552332-71-5
- Formula: C23H22N4O
- Molecular Weight:370.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
|
Akt1 360 nM (IC50) |
In Vitro
DB07107 is more effective in blocking drug-resistant T315I mutant than the wild-type Bcr-Abl. DB07107 (C23H22N4O) from DrugBank showed the highest binding energy with XP score of -14.045 kcal/mol[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 552332-71-5
-
Molecular Weight 370.45
-
Formula C23H22N4O
-
SMILES
N[C@@H](COC1=CN=CC(/C=C/C2=CC=NC=C2)=C1)CC3=CNC4=C3C=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
[1]. Banavath HN, et al. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study. Sci Rep. 2014 Nov 10;4:6948. [Content Brief]
[2]. Li Q, et al. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1679-85. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DB07107 Related Classifications
HY-123390 Related Classifications
Powered by Bioz